CareDX Inc. failed to save its patents related to organ transplant rejection tests, as the Federal Circuit affirmed that the inventions are ineligible for patents.
The patents—which describe a breakthrough way to measure organ transplant rejection with a blood test—observe a natural phenomenon, meaning they’re not eligible for patent protection under US Supreme Court precedent, the US Court of Appeals for the Federal Circuit ruled. The inventions use new techniques, not created by the same scientists, to measure the amount of the donor’s DNA leeching from transplanted organs.
Because the “patents are directed to a natural law together with conventional ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.